Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval

Odronextamab Was Filed For FL And DLBCL

The company received two complete response letters from the US FDA for the CD20xCD3 bispecific antibody odronextamab due to clinical trial requirements for accelerated approval.

no
FDA rejected Regeneron's BLAs for odronextamab • Source: Shutterstock

More from Anticancer

More from Therapy Areas